Progenics Pharmaceut (PGNX) 4.64 $PGNX
Bradley Campbell, President and COO of Amicus Therapeutics, elected to Progenics Board of Directors
GlobeNewswire - Thu Jun 09, 7:00AM CDT
Progenics Pharmaceuticals, Inc. (Nasdaq
GNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, today announced the election of Bradley Campbell to the Company's Board of Directors. Mr. Campbell brings to Progenics extensive experience in the biopharmaceutical industry, with particular expertise in the areas of corporate strategy, commercial operations and planning, business development and sales and marketing. He currently serves as President and Chief Operating Officer of Amicus Therapeutics, a biotechnology company focused on the development of therapies for a broad range of rare and orphan diseases.
PGNX: 4.64 (-0.04), FOLD: 6.05 (-0.66)
Progenics Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Thu Jun 02, 7:30AM CDT
Progenics Pharmaceuticals, Inc., (Nasdaq GNX), an oncology company focused on developing innovative medicines and other products for targeting and treating cancer, announced today that Mark R. Baker, Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 at 11:30 a.m. Eastern Time. The conference is being held at the Grand Hyatt in New York, NY.
PGNX: 4.64 (-0.04)
Progenics reports 1Q loss
Automated Insights - Thu May 05, 8:48AM CDT
TARRYTOWN, N.Y. (AP) _ Progenics Pharmaceuticals Inc. (PGNX) on Thursday reported a loss of $12.7 million in its first quarter.
PGNX: 4.64 (-0.04)
Progenics Pharmaceuticals Announces First Quarter 2016 Financial and Business Results
GlobeNewswire - Thu May 05, 6:30AM CDT
-- On May 2nd, the Company Announced It Had Granted Exclusive World-Wide Rights to Bayer to Develop and Commercialize Products Using Progenics' PSMA Antibody Technology In Combination with Alpha-Emitting Radionuclides
PGNX: 4.64 (-0.04)
Progenics Licenses PSMA Antibody Technology to Bayer for Development of Alpha-Radiolabeled Therapeutic Antibodies
GlobeNewswire - Mon May 02, 7:30AM CDT
Progenics Pharmaceuticals, Inc. (Nasdaq GNX) today announced that it has granted an exclusive license to Bayer for the development and commercialization of therapeutic antibodies combining the Company's prostate specific membrane antigen (PSMA) antibody technology with Bayer's targeted thorium conjugate technology.
PGNX: 4.64 (-0.04)
Progenics Pharmaceuticals Sets First Quarter 2016 Financial Results Call for May 5
GlobeNewswire - Thu Apr 21, 7:31AM CDT
Progenics Pharmaceuticals, Inc., (Nasdaq GNX), an oncology company focused on developing innovative ways to target and treat prostate cancer, announced today that it will host a conference call and webcast to review the first quarter ended March 31, 2016 financial results on Thursday, May 5, 2016, at 8:30 a.m. ET.
PGNX: 4.64 (-0.04)
Market Exclusive Research Weekly Biotech Report
ACCESSWIRE - Mon Apr 18, 8:27AM CDT
NEW YORK, NY / ACCESSWIRE / April 18, 2016 / The week just gone gave us plenty to talk about in the biotech space, with two significant developments - one in oncology and one in a rare genetic growth disorder called acromegaly. Here's what happened, and how things played out as a result.
PGNX: 4.64 (-0.04), CLVS: 14.11 (-1.12), SRPT: 19.95 (-1.04), COLL: 16.17 (-0.32), CHMA: 2.91 (-0.23)
Progenics Pharmaceuticals to Present at the 15th Annual Needham Healthcare Conference
GlobeNewswire - Wed Apr 06, 4:00PM CDT
Progenics Pharmaceuticals, Inc. (Nasdaq GNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, announced today that Mark R. Baker, CEO, is scheduled to present at the 15th Annual Needham Healthcare Conference on Wednesday, April 13, 2016 at 8:40 a.m. Eastern Time. The conference is being held at The Westin Grand Central Hotel in New York, NY.
PGNX: 4.64 (-0.04)
Valeant and Progenics Announce PDUFA Date Extension for Oral RELISTOR
PR Newswire - Mon Apr 04, 6:00AM CDT
Agency requests standard three-month extension to review additional solicited information-
PGNX: 4.64 (-0.04), VRX: 24.14 (-1.34), VRX.TO: 30.80 (-1.39)
Biotech Sector Report Analyst; Expecting FDA Results
ACCESSWIRE - Mon Mar 28, 7:02AM CDT
NEW YORK, NY / ACCESSWIRE / March 28, 2016 / MannKind Corporation (NASDAQ: MNKD), Keryx Biopharmaceuticals. (NASDAQ: KERX), Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX), and BIND Therapeutics Inc. (NASDAQ: BIND) are four tickers in the biotech space currently suffering due to the overall poor market sentiment towards the space. The biotech sector has had a cruel start to the year. The Nasdaq Biotechnology Index is down 18% so far in 2016, and is now off about 30% since its July peak. This fall in market value has led to potential opportunities for big players in the space to pick up valuable assets are very low prices. While large drugmakers have hardly been exempt from the pain, the selloff should present a chance for them to find some cheap deals. Additionally, the four companies described here are expecting results from the FDA which may lead to even more upside for the junior biotech sector.
PGNX: 4.64 (-0.04), BIND: 0.40 (-0.01), MNKD: 1.01 (-0.02), KERX: 5.93 (-0.12)
Progenics Pharmaceuticals to Present at 28th Annual ROTH Conference
GlobeNewswire - Wed Mar 09, 4:00PM CST
Progenics Pharmaceuticals, Inc., (Nasdaq GNX), an oncology company focused on developing innovative ways to target and treat cancer, announced today that Mark R. Baker, CEO, will present at the 28 Annual ROTH Conference in Dana Point, CA on Wednesday March 16, 2016 at 9:30 a.m. Pacific Time.
PGNX: 4.64 (-0.04)
Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) Phase III Clinical Trial Expected; Analyst Report
ACCESSWIRE - Tue Feb 09, 8:05AM CST
CHICAGO, IL / ACCESSWIRE / February 9, 2016 / Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) an oncology company focused on developing innovative ways to target and treat cancer, recently announced that it has begun enrollment in its pivotal Phase 3 clinical trial evaluating 1404, a small molecule being developed as an imaging agent for prostate cancer. 1404 targets prostate specific membrane antigen (PSMA), which is abundantly expressed on prostate cancer cells. This Phase 3 clinical trial is expected to enroll approximately 450 patients with newly diagnosed low-grade prostate cancer who are candidates for active surveillance, but nonetheless are planning to undergo radical prostatectomy.
PGNX: 4.64 (-0.04)
Global Progenics Pharmaceuticals, Inc. Market Size, Share, Trend, Growth, Analysis and Forecast Report Product Pipeline Review 2015 - Acute Market Reports
M2 - Fri Feb 05, 7:59AM CST
'PROGENICS PHARMACEUTICALS, INC. - Product Pipeline Review - 2015', provides an overview of the PROGENICS PHARMACEUTICALS, INC.'s pharmaceutical research and development focus.
PGNX: 4.64 (-0.04)
Progenics Pharmaceuticals to Present at Upcoming Investor Conferences
GlobeNewswire - Mon Feb 01, 7:45AM CST
Progenics Pharmaceuticals, Inc., (Nasdaq GNX), an oncology company focused on developing innovative ways to target and treat cancer, announced today that Mark R. Baker, CEO, will present at two upcoming investor conferences:
PGNX: 4.64 (-0.04)
Neuroblastoma - Pipeline Review, H2 2015
M2 - Thu Jan 28, 5:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/lzkrbt/neuroblastoma) has announced the addition of the "Neuroblastoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Neuroblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuroblastoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Neuroblastoma Overview - Therapeutics Development - Pipeline Products for Neuroblastoma - Overview - Pipeline Products for Neuroblastoma - Comparative Analysis - Neuroblastoma - Therapeutics under Development by Companies - Neuroblastoma - Therapeutics under Investigation by Universities/Institutes - Neuroblastoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Neuroblastoma - Products under Development by Companies - Neuroblastoma - Products under Investigation by Universities/Institutes - Neuroblastoma - Companies Involved in Therapeutics Development - Ability Pharma, SL - Acetylon Pharmaceuticals, Inc. - Advanced Accelerator Applications SA - Ampio Pharmaceuticals, Inc. - APEIRON Biologics AG - AstraZeneca Plc - ATLAB Pharma SAS - Bellicum Pharmaceuticals, Inc. - Bexion Pharmaceuticals, LLC. - BioLineRx, Ltd. - Bionucleon Srl - Biotec Pharmacon ASA - Cebiotex, S.L. - Celgene Corporation - Chugai Pharmaceutical Co., Ltd. - Cleveland BioLabs, Inc. - CureFAKtor Pharmaceuticals, LLC - Cyclacel Pharmaceuticals, Inc. - DEKK-TEC, Inc. - Errant Gene Therapeutics, LLC - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Ignyta, Inc. - Juno Therapeutics Inc. - Lindis Biotech GmbH - MabVax Therapeutics Holdings, Inc. - MEI Pharma, Inc. - Merck & Co., Inc. - Merrimack Pharmaceuticals, Inc. - Novartis AG - Novogen Limited - Pharmacyclics, Inc. - Pono Pharma - Progenics Pharmaceuticals, Inc. - Recombio S.L For more information visit http://www.researchandmarkets.com/research/lz...roblastoma
PCYC: 261.25 (+1.70), AMPE: 3.67 (-0.16), GSK: 40.93 (-1.13), MEIP: 1.39 (-0.02), AAAP: 31.26 (-0.67), MACK: 6.32 (-0.24), PGNX: 4.64 (-0.04), BLCM: 12.91 (-0.03), CYCC: 5.95 (-0.14), RXDX: 5.79 (-0.22), MRK: 56.81 (-0.37), AZN: 27.97 (-0.99), JUNO: 42.98 (-2.55), CBLI: 2.61 (+0.01), NVS: 78.94 (-1.57), CELGZ: 1.46 (-0.04)
Biotechnology Stocks Technical Data -- Regulus Therapeutics, Progenics Pharma, Spectrum Pharma, and Sorrento Therapeutics
ACCESSWIRE - Tue Jan 12, 7:01AM CST
NEW YORK, NY / ACCESSWIRE / January 12, 2016 / Park Lane Advisor has initiated coverage on the following equities: Regulus Therapeutics Inc. (NASDAQ: RGLS), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI), and Sorrento Therapeutics Inc. (NASDAQ: SRNE). Free research report on Regulus Therapeutics can be accessed at http://www.parklaneadvisor.com/ On Monday, January 11, 2016, the NASDAQ Composite ended at 4,637.99, down 0.12%, the Dow Jones Industrial Average advanced 0.32%, to finish the day at 16,398.57, and the S&P 500 closed at 1,923.67, up 0.09%. The gains were broad based as six out of nine sectors ended the session in positive. Register for your complimentary reports at the links given below.
PGNX: 4.64 (-0.04), SPPI: 6.94 (-0.03), RGLS: 5.27 (-0.07), SRNE: 6.34 (-0.10)
Progenics Pharmaceuticals Commences Pivotal Phase 3 Study of PSMA Targeted Imaging Agent 1404 for Prostate Cancer
GlobeNewswire - Thu Jan 07, 7:30AM CST
Progenics Pharmaceuticals, Inc. (Nasdaq GNX) announced today that it has begun enrollment in its pivotal Phase 3 clinical trial evaluating 1404, a small molecule being developed as an imaging agent for prostate cancer. 1404 targets prostate specific membrane antigen (PSMA), which is abundantly expressed on prostate cancer cells.
PGNX: 4.64 (-0.04)
Progenics Pharmaceuticals Down 13.0% Since SmarTrend Downtrend Call (PGNX)
Comtex SmarTrend(R) - Wed Jan 06, 5:30PM CST
SmarTrend identified a Downtrend for Progenics Pharmaceuticals (NASDAQ GNX) on November 16th, 2015 at $6.49. In approximately 2 months, Progenics Pharmaceuticals has returned 13.03% as of today's recent price of $5.64.
PGNX: 4.64 (-0.04)
Bradley Campbell, President and COO of Amicus Therapeutics, elected to Progenics Board of Directors
GlobeNewswire - Thu Jun 09, 7:00AM CDT
Progenics Pharmaceuticals, Inc. (Nasdaq
GNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, today announced the election of Bradley Campbell to the Company's Board of Directors. Mr. Campbell brings to Progenics extensive experience in the biopharmaceutical industry, with particular expertise in the areas of corporate strategy, commercial operations and planning, business development and sales and marketing. He currently serves as President and Chief Operating Officer of Amicus Therapeutics, a biotechnology company focused on the development of therapies for a broad range of rare and orphan diseases. PGNX: 4.64 (-0.04), FOLD: 6.05 (-0.66)
Progenics Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Thu Jun 02, 7:30AM CDT
Progenics Pharmaceuticals, Inc., (Nasdaq
GNX), an oncology company focused on developing innovative medicines and other products for targeting and treating cancer, announced today that Mark R. Baker, Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 at 11:30 a.m. Eastern Time. The conference is being held at the Grand Hyatt in New York, NY. PGNX: 4.64 (-0.04)
Progenics reports 1Q loss
Automated Insights - Thu May 05, 8:48AM CDT
TARRYTOWN, N.Y. (AP) _ Progenics Pharmaceuticals Inc. (PGNX) on Thursday reported a loss of $12.7 million in its first quarter.
PGNX: 4.64 (-0.04)
Progenics Pharmaceuticals Announces First Quarter 2016 Financial and Business Results
GlobeNewswire - Thu May 05, 6:30AM CDT
-- On May 2nd, the Company Announced It Had Granted Exclusive World-Wide Rights to Bayer to Develop and Commercialize Products Using Progenics' PSMA Antibody Technology In Combination with Alpha-Emitting Radionuclides
PGNX: 4.64 (-0.04)
Progenics Licenses PSMA Antibody Technology to Bayer for Development of Alpha-Radiolabeled Therapeutic Antibodies
GlobeNewswire - Mon May 02, 7:30AM CDT
Progenics Pharmaceuticals, Inc. (Nasdaq
GNX) today announced that it has granted an exclusive license to Bayer for the development and commercialization of therapeutic antibodies combining the Company's prostate specific membrane antigen (PSMA) antibody technology with Bayer's targeted thorium conjugate technology. PGNX: 4.64 (-0.04)
Progenics Pharmaceuticals Sets First Quarter 2016 Financial Results Call for May 5
GlobeNewswire - Thu Apr 21, 7:31AM CDT
Progenics Pharmaceuticals, Inc., (Nasdaq
GNX), an oncology company focused on developing innovative ways to target and treat prostate cancer, announced today that it will host a conference call and webcast to review the first quarter ended March 31, 2016 financial results on Thursday, May 5, 2016, at 8:30 a.m. ET. PGNX: 4.64 (-0.04)
Market Exclusive Research Weekly Biotech Report
ACCESSWIRE - Mon Apr 18, 8:27AM CDT
NEW YORK, NY / ACCESSWIRE / April 18, 2016 / The week just gone gave us plenty to talk about in the biotech space, with two significant developments - one in oncology and one in a rare genetic growth disorder called acromegaly. Here's what happened, and how things played out as a result.
PGNX: 4.64 (-0.04), CLVS: 14.11 (-1.12), SRPT: 19.95 (-1.04), COLL: 16.17 (-0.32), CHMA: 2.91 (-0.23)
Progenics Pharmaceuticals to Present at the 15th Annual Needham Healthcare Conference
GlobeNewswire - Wed Apr 06, 4:00PM CDT
Progenics Pharmaceuticals, Inc. (Nasdaq
GNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, announced today that Mark R. Baker, CEO, is scheduled to present at the 15th Annual Needham Healthcare Conference on Wednesday, April 13, 2016 at 8:40 a.m. Eastern Time. The conference is being held at The Westin Grand Central Hotel in New York, NY. PGNX: 4.64 (-0.04)
Valeant and Progenics Announce PDUFA Date Extension for Oral RELISTOR
PR Newswire - Mon Apr 04, 6:00AM CDT
Agency requests standard three-month extension to review additional solicited information-
PGNX: 4.64 (-0.04), VRX: 24.14 (-1.34), VRX.TO: 30.80 (-1.39)
Biotech Sector Report Analyst; Expecting FDA Results
ACCESSWIRE - Mon Mar 28, 7:02AM CDT
NEW YORK, NY / ACCESSWIRE / March 28, 2016 / MannKind Corporation (NASDAQ: MNKD), Keryx Biopharmaceuticals. (NASDAQ: KERX), Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX), and BIND Therapeutics Inc. (NASDAQ: BIND) are four tickers in the biotech space currently suffering due to the overall poor market sentiment towards the space. The biotech sector has had a cruel start to the year. The Nasdaq Biotechnology Index is down 18% so far in 2016, and is now off about 30% since its July peak. This fall in market value has led to potential opportunities for big players in the space to pick up valuable assets are very low prices. While large drugmakers have hardly been exempt from the pain, the selloff should present a chance for them to find some cheap deals. Additionally, the four companies described here are expecting results from the FDA which may lead to even more upside for the junior biotech sector.
PGNX: 4.64 (-0.04), BIND: 0.40 (-0.01), MNKD: 1.01 (-0.02), KERX: 5.93 (-0.12)
Progenics Pharmaceuticals to Present at 28th Annual ROTH Conference
GlobeNewswire - Wed Mar 09, 4:00PM CST
Progenics Pharmaceuticals, Inc., (Nasdaq
GNX), an oncology company focused on developing innovative ways to target and treat cancer, announced today that Mark R. Baker, CEO, will present at the 28 Annual ROTH Conference in Dana Point, CA on Wednesday March 16, 2016 at 9:30 a.m. Pacific Time. PGNX: 4.64 (-0.04)
Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) Phase III Clinical Trial Expected; Analyst Report
ACCESSWIRE - Tue Feb 09, 8:05AM CST
CHICAGO, IL / ACCESSWIRE / February 9, 2016 / Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) an oncology company focused on developing innovative ways to target and treat cancer, recently announced that it has begun enrollment in its pivotal Phase 3 clinical trial evaluating 1404, a small molecule being developed as an imaging agent for prostate cancer. 1404 targets prostate specific membrane antigen (PSMA), which is abundantly expressed on prostate cancer cells. This Phase 3 clinical trial is expected to enroll approximately 450 patients with newly diagnosed low-grade prostate cancer who are candidates for active surveillance, but nonetheless are planning to undergo radical prostatectomy.
PGNX: 4.64 (-0.04)
Global Progenics Pharmaceuticals, Inc. Market Size, Share, Trend, Growth, Analysis and Forecast Report Product Pipeline Review 2015 - Acute Market Reports
M2 - Fri Feb 05, 7:59AM CST
'PROGENICS PHARMACEUTICALS, INC. - Product Pipeline Review - 2015', provides an overview of the PROGENICS PHARMACEUTICALS, INC.'s pharmaceutical research and development focus.
PGNX: 4.64 (-0.04)
Progenics Pharmaceuticals to Present at Upcoming Investor Conferences
GlobeNewswire - Mon Feb 01, 7:45AM CST
Progenics Pharmaceuticals, Inc., (Nasdaq
GNX), an oncology company focused on developing innovative ways to target and treat cancer, announced today that Mark R. Baker, CEO, will present at two upcoming investor conferences: PGNX: 4.64 (-0.04)
Neuroblastoma - Pipeline Review, H2 2015
M2 - Thu Jan 28, 5:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/lzkrbt/neuroblastoma) has announced the addition of the "Neuroblastoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Neuroblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuroblastoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Neuroblastoma Overview - Therapeutics Development - Pipeline Products for Neuroblastoma - Overview - Pipeline Products for Neuroblastoma - Comparative Analysis - Neuroblastoma - Therapeutics under Development by Companies - Neuroblastoma - Therapeutics under Investigation by Universities/Institutes - Neuroblastoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Neuroblastoma - Products under Development by Companies - Neuroblastoma - Products under Investigation by Universities/Institutes - Neuroblastoma - Companies Involved in Therapeutics Development - Ability Pharma, SL - Acetylon Pharmaceuticals, Inc. - Advanced Accelerator Applications SA - Ampio Pharmaceuticals, Inc. - APEIRON Biologics AG - AstraZeneca Plc - ATLAB Pharma SAS - Bellicum Pharmaceuticals, Inc. - Bexion Pharmaceuticals, LLC. - BioLineRx, Ltd. - Bionucleon Srl - Biotec Pharmacon ASA - Cebiotex, S.L. - Celgene Corporation - Chugai Pharmaceutical Co., Ltd. - Cleveland BioLabs, Inc. - CureFAKtor Pharmaceuticals, LLC - Cyclacel Pharmaceuticals, Inc. - DEKK-TEC, Inc. - Errant Gene Therapeutics, LLC - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Ignyta, Inc. - Juno Therapeutics Inc. - Lindis Biotech GmbH - MabVax Therapeutics Holdings, Inc. - MEI Pharma, Inc. - Merck & Co., Inc. - Merrimack Pharmaceuticals, Inc. - Novartis AG - Novogen Limited - Pharmacyclics, Inc. - Pono Pharma - Progenics Pharmaceuticals, Inc. - Recombio S.L For more information visit http://www.researchandmarkets.com/research/lz...roblastoma
PCYC: 261.25 (+1.70), AMPE: 3.67 (-0.16), GSK: 40.93 (-1.13), MEIP: 1.39 (-0.02), AAAP: 31.26 (-0.67), MACK: 6.32 (-0.24), PGNX: 4.64 (-0.04), BLCM: 12.91 (-0.03), CYCC: 5.95 (-0.14), RXDX: 5.79 (-0.22), MRK: 56.81 (-0.37), AZN: 27.97 (-0.99), JUNO: 42.98 (-2.55), CBLI: 2.61 (+0.01), NVS: 78.94 (-1.57), CELGZ: 1.46 (-0.04)
Biotechnology Stocks Technical Data -- Regulus Therapeutics, Progenics Pharma, Spectrum Pharma, and Sorrento Therapeutics
ACCESSWIRE - Tue Jan 12, 7:01AM CST
NEW YORK, NY / ACCESSWIRE / January 12, 2016 / Park Lane Advisor has initiated coverage on the following equities: Regulus Therapeutics Inc. (NASDAQ: RGLS), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI), and Sorrento Therapeutics Inc. (NASDAQ: SRNE). Free research report on Regulus Therapeutics can be accessed at http://www.parklaneadvisor.com/ On Monday, January 11, 2016, the NASDAQ Composite ended at 4,637.99, down 0.12%, the Dow Jones Industrial Average advanced 0.32%, to finish the day at 16,398.57, and the S&P 500 closed at 1,923.67, up 0.09%. The gains were broad based as six out of nine sectors ended the session in positive. Register for your complimentary reports at the links given below.
PGNX: 4.64 (-0.04), SPPI: 6.94 (-0.03), RGLS: 5.27 (-0.07), SRNE: 6.34 (-0.10)
Progenics Pharmaceuticals Commences Pivotal Phase 3 Study of PSMA Targeted Imaging Agent 1404 for Prostate Cancer
GlobeNewswire - Thu Jan 07, 7:30AM CST
Progenics Pharmaceuticals, Inc. (Nasdaq
GNX) announced today that it has begun enrollment in its pivotal Phase 3 clinical trial evaluating 1404, a small molecule being developed as an imaging agent for prostate cancer. 1404 targets prostate specific membrane antigen (PSMA), which is abundantly expressed on prostate cancer cells. PGNX: 4.64 (-0.04)
Progenics Pharmaceuticals Down 13.0% Since SmarTrend Downtrend Call (PGNX)
Comtex SmarTrend(R) - Wed Jan 06, 5:30PM CST
SmarTrend identified a Downtrend for Progenics Pharmaceuticals (NASDAQ
GNX) on November 16th, 2015 at $6.49. In approximately 2 months, Progenics Pharmaceuticals has returned 13.03% as of today's recent price of $5.64. PGNX: 4.64 (-0.04)
